1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Divi's Laboratories Limited

Divi's Laboratories Limited

9,162.00
INR
-28.00
(-0.30%)
104.73EPS
62.82P/E
1.75TMarket Cap
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
95.38
117.34
141.98
152.68
143.42
180.96
199.31
258.35
331.46
288.73
293.67
351.27
394.62
411.42
Basic EPS, GAAP
29.13
32.08
42.41
39.95
33.04
50.96
51.85
74.75
111.52
68.71
60.27
82.53
96.73
104.73
Free Cash Flow per Basic Share
11.69
19.55
24.19
29.14
18.91
8.33
1.23
39.05
45.15
74.81
9.72
8.1
8.21
- -
Dividend per Share
8.77
11.7
24.07
- -
12.03
12.06
38.58
- -
20
29.98
29.98
29.98
30.02
- -
Book Value per Share
111.63
143.98
161.73
201.81
223.18
262.07
275.36
350.12
441.79
480.92
511.21
563.87
631.37
- -
Tangible Book Value per Share
111.63
143.84
161.62
201.69
222.94
261.92
275.22
349.93
441.51
480.73
511.06
563.72
631.15
- -
Basic Weighted Avg Shares
265
265
265
265
265
265
265
265
265
265
265
265
265
266
Sales/Revenue/Turnover
25,321
31,149
37,690
40,533
38,075
48,038
52,912
68,583
87,992
76,650
77,960
93,250
104,760
109,250
Operating Margin (%)
36.71
33.35
34.62
33.66
29.59
35.61
31.01
38.14
40.61
26.44
23.5
27.57
28.44
30.43
Depreciation Expense
921
1,360
1,182
1,233
1,425
1,689
1,862
2,556
3,115
3,430
3,780
4,020
4,630
4,830
Net Income, GAAP
7,733
8,515
11,258
10,604
8,770
13,527
13,765
19,843
29,605
18,240
16,000
21,910
25,680
27,810
Effective Tax Rate (%)
21.96
20.57
19.17
24
28.78
27.08
24.34
25.57
19.63
23.01
26.03
24.86
24.2
23.93
Profit Margin (%)
30.54
27.34
29.87
26.16
23.03
28.16
26.02
28.93
33.64
23.8
20.52
23.5
24.51
25.46
Working Capital
16,289
23,175
25,075
33,511
38,817
38,033
37,530
50,623
71,560
82,110
83,970
86,290
90,530
- -
LT Debt
- -
- -
- -
- -
- -
- -
45
37
29
30
20
20
50
- -
Total Equity
29,633
38,223
42,933
53,574
59,248
69,572
73,099
92,946
117,282
127,670
135,710
149,690
167,610
- -
Return on Invested Capital (%)
26.12
23.97
25.64
21.32
14.01
19.08
17.19
23.33
27.28
12.74
10.24
13.48
13.88
- -
Return on Capital (%)
28.09
24.95
27.56
21.82
15.42
20.75
19.16
23.84
28.16
14.89
12.16
15.36
16.29
- -
Return on Common Equity (%)
28.31
25.1
27.74
21.98
15.55
21
19.3
23.9
28.16
14.89
12.15
15.35
16.19
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
20
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
50
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
265
Market Capitalization
1,697,008
1,578,742
1,746,518

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
110,960
- -
Cash, Cash Equivalents & STI
- -
32,360
- -
Accounts Receivable, Net
- -
29,840
- -
Inventories
- -
39,540
- -
Total Current Liabilities
- -
20,430
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
20
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.86%
12.72%
11.97%
Free Cash Flow
289.08%
-4.2%
1.4%
Net Income, GAAP
12.97%
10.53%
17.21%
Sales/Revenue/Turnover
11.65%
9.81%
12.34%
Total Cash Common Dividend
- -
- -
0.13%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
21,180
23,380
23,190
25,850
93,250
2026
24,100
- -
26,040
28,310
104,760
2027
30,800
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.2
19.2
22.2
24.93
82.53
2026
20.49
- -
21.98
28.31
96.73
2027
33.95
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
29.98
2026
- -
- -
- -
- -
30.02
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Satchandra Kiran Divi
Full Time Employees
19,292
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Divi Towers Hyderabad TS India 500032
IPO Date
Jun 25, 1905
Website
divislabs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Merck & Company, Inc. (NYSE:MRK)
Business
Divi's Laboratories Limited (DIVISLAB.NS) manufactures active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients; provides custom synthesis services for generic APIs and advanced intermediates to global pharmaceutical companies; and supplies carotenoids such as beta-carotene, astaxanthin, lycopene and canthaxanthin, along with vitamins and lutein to the nutritional, pharmaceutical, food, beverage and feed industries. The company offers a portfolio of approximately 30 commercial generic APIs across therapeutic categories including antidepressants (e.g., bupropion HCl, venlafaxine HCl), antineoplastics (e.g., capecitabine), antiparkinson agents (e.g., carbidopa, levodopa), antihypertensives (e.g., diltiazem HCl, irbesartan), analgesics (e.g., dextromethorphan, naproxen), anticonvulsants (e.g., gabapentin, lacosamide), antivirals (e.g., valacyclovir HCl) and contrast media (e.g., iopamidol, iohexol). Founded in 1990 and headquartered in Hyderabad, India, Divi's operates three manufacturing units with over 16,500 cubic meters of annual capacity, three R&D centers staffed by more than 700 scientists, and quality teams exceeding 2,000 analysts; it exports to over 100 countries across North America, Europe, Asia and other regions. In recent developments, Divi's entered a long-term manufacturing and supply agreement in May 2025 with an international pharmaceutical company for advanced intermediates, prompting plans to invest INR 650-750 crore in capacity expansion funded by customer advances, with operations targeted by January 2027; the deal anticipates meaningful long-term revenue contributions without external financing or structural changes. The company maintains a subsidiary, Divi's Nutraceuticals, and reported consolidated net profit growth to INR 662 crore in the March 2025 quarter alongside revenue of INR 2,585 crore.